drugset
drugset / Trial / NCT03351751

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects

NCT03351751 ↗

Phase 1 Completed 19 enrolled Pfizer
RandomizedSequentialDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple repeat oral doses of PF-06372865 in healthy adult subjects.

Timeline

Start
2017-11-08
Primary completion
2018-02-28
Completion
2018-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Darigabat Small molecule — Oral

Indications

No indication recorded.